The likelihood of discontinuing treatment with Tysabri (natalizumab) is higher among patients with progressive relapsing multiple sclerosis, and those who smoke and are depressed, a study reported. Progressive relapsing MS (PRMS) is now largely considered a subset of primary progressive MS, or PPMS marked by periods of activity (at the time of relapses or new MRI lesions). The study Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population was published in the Multiple SclerosisJournal Experimental, Translational andClinical. Continue reading →

AB Sciencesmasitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show. Masitinib, formerly known as AB1010, is an oral therapy that inhibits the activity of cells in the innate immune system, specifically mast cells, microglia, and macrophages. Continue reading →

The drug maker said that in March it would begin two more clinical trials of remdesivir, an experimental antiviral drug, in more nations outside China. The drug maker Gilead Sciences is expanding its clinical trials of the antiviral drug remdesivir as a possible coronavirus treatment into several countries outside China, the company announced on Wednesday. Two new clinical trials of remdesivir are to begin in March, involving approximately 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, Gilead said in a statement Continue reading →

Investment Thesis I last posted about TG Therapeutics (TGTX) in November last year after the company published long-awaited positive trial data concerning flagship drugs umbralisib and ublituximab, which caused a small uptick in the share price from ~$5 to ~$9. I felt that TG was edging closer to commercialising its first drug and recommended its stock as a speculative investment - since then the share price has continued to grow and has reached $16 at the time of posting this update on further positive news flow. The next few months promise to be a critical period for the company. Continue reading →

A study being carried out in Nottingham aims to pave the way for more personalised treatments for patients with Multiple Sclerosis (MS). Each day, around 14 people are diagnosed with the debilitating disease that can leave people struggling to walk, feeing tired and experiencing muscle weakness or spasms. Continue reading →

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc., Inc. Continue reading →

RALEIGH, N.C., Feb. Continue reading →

From helping son Jensen deal with a tumor to developing a CBD product, its a story of many chapters LYNDEN The story has been written over time and across chapters. It involves a Lynden family with multiple businesses, a child who left hospice at age 4 to live on into his teen years, a mother living with multiple sclerosis, an appearance on TV, a big beautiful white barn and farmhouse. And the future is still being written and lived Continue reading →

The Progressive Relapsing Multiple Sclerosis Treatment Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency. Continue reading →